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Abstract
Background: Notch receptors normally play a key role in guiding a variety of cell fate decisions during development and
differentiation of metazoan organisms. On the other hand, dysregulation of Notch1 signaling is associated with many
different types of cancer as well as tumor angiogenesis, making Notch1 a potential therapeutic target.
Principal Findings: Here we report the in vitro activities of inhibitory Notch1 monoclonal antibodies derived from cell-based
and solid-phase screening of a phage display library. Two classes of antibodies were found, one directed against the EGF-
repeat region that encompasses the ligand-binding domain (LBD), and the second directed against the activation switch of
the receptor, the Notch negative regulatory region (NRR). The antibodies are selective for Notch1, inhibiting Jag2-
dependent signaling by Notch1 but not by Notch 2 and 3 in reporter gene assays, with EC50 values as low as 563 nM and
0.1360.09 nM for the LBD and NRR antibodies, respectively, and fail to recognize Notch4. While more potent, NRR
antibodies are incomplete antagonists of Notch1 signaling. The antagonistic activity of LBD, but not NRR, antibodies is
strongly dependent on the activating ligand. Both LBD and NRR antibodies bind to Notch1 on human tumor cell lines and
inhibit the expression of sentinel Notch target genes, including HES1, HES5, and DTX1. NRR antibodies also strongly inhibit
ligand-independent signaling in heterologous cells transiently expressing Notch1 receptors with diverse NRR ‘‘class I’’ point
mutations, the most common type of mutation found in human T-cell acute lymphoblastic leukemia (T-ALL). In contrast,
NRR antibodies failed to antagonize Notch1 receptors bearing rare ‘‘class II’’ or ‘‘class III’’ mutations, in which amino acid
insertions generate a duplicated or constitutively sensitive metalloprotease cleavage site. Signaling in T-ALL cell lines
bearing class I mutations is partially refractory to inhibitory antibodies as compared to cell-penetrating gamma-secretase
inhibitors.
Conclusions/Significance: Antibodies that compete with Notch1 ligand binding or that bind to the negative regulatory
region can act as potent inhibitors of Notch1 signaling. These antibodies may have clinical utility for conditions in which
inhibition of signaling by wild-type Notch1 is desired, but are likely to be of limited value for treatment of T-ALLs associated
with aberrant Notch1 activation.
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Notch signals normally participate in a variety of cellular
processes, including cell fate specification, differentiation, prolif-
eration, apoptosis, migration, and angiogenesis [1]. The four
mammalian Notch receptors (Notch1-4) all have a similar modular
domain organization. The extracellular domain contains a series
of epidermal growth factor (EGF)-like repeats that participate in
binding to ligands [2], followed by a negative regulatory domain
(NRR) that, in the absence of ligand, maintains the receptor in a
protease-resistant conformation [3,4]. During trafficking to the cell
surface, the NRR is clipped by a furin-like protease at a site called
S1 [5], dividing Notch into two subunits that are held together by
contacts in the N-terminal and C-terminal portions of the NRR.
The intracellular portion of Notch (ICN) contains RAM [6] and
ankyrin-repeat domains that both participate in binding to the
DNA-binding factor CSL [for CBF-1/Su(H)/Lag1] [7], as well as
nuclear localization sequences and a C-terminal PEST degron [8].
Activation of Notch receptors is normally induced by binding of
Jagged [9,10] or Delta-like [11–13] ligands expressed on neighbor-
ing cells, which initiates a series of additional proteolytic cleavages.
The first is catalyzed by a metalloprotease of the ADAM (a
disintegrin and metalloprotease) family [14,15] and occurs at a site
called S2, which lies within the NRR just external to the
transmembrane domain. This primes Notch for additional
cleavages within the transmembrane domain that are carried out
by the multiprotein membrane complex c-secretase [16]. The final
cleavage liberates ICN from the membrane, allowing it to enter the
nucleus and activate the transcription of Notch-responsive genes
(e.g., HES1, HES5, NRARP, Deltex1 (DTX1), c-MYC). This depends
on binding of ICN to the transcription factor CSL [7,17,18] and
recruitment of Mastermind-like coactivators [19–22]. Post-transla-
tional modification events, such as glycosylation of the extracellular
domains of both receptor and ligands also play an important role in
Notch-ligand interactions [23,24], and such modifications may play
a part in tissue-specific responses to various ligands [25].
In addition to its developmental roles, dysregulation of Notch
signaling is associated with a number of different cancers. The
clearest example is T-cell acute lymphoblastic leukemia/lympho-
ma (T-ALL, see below), in which activating mutations in the NRR
and/or the PEST domain of Notch1 are found in over 50% of
cases. Increases in Notch signaling, perhaps induced by ligand-
mediated activation, have also been associated with breast, colon,
ovarian, and lung cancer [26–30]. For example, co-expression of
Notch1 and Jag1 has been associated with poor outcomes in
patients with breast cancer [31]. Delta-like-4 signaling through
Notch1 regulates the formation of tip cells during angiogenesis
[32] and is also likely to play an important role in pathological
angiogenesis [33], making it a promising therapeutic target [34].
The discovery of gain-of-function Notch1 mutations in 55–60%
of human primary T-ALL samples [26], including all of the major
T-ALL subtypes, greatly expanded the known role of Notch1 in
this disease, moving it to the center of T-ALL pathogenesis. The
most common leukemogenic Notch1 mutations (35–40% of
tumors) lie in the ‘‘heterodimerization domain’’ (HD) of the
NRR and lead to ligand-independent Notch signaling activity
[35,36]. Mutations that result in deletion of the PEST degron (20–
30% of tumors) are also frequent in T-ALL and cause a synergistic
increase in Notch signaling when aligned in cis with HD mutations
in the same Notch1 allele [35–37]. Notch1 signaling drives the
growth of T-ALL cells [38,39], making it an attractive target for
rational pharmacological intervention.
A number of different strategies [34] are in development to
inhibit Notch signaling for therapeutic purposes. One approach is
to block the proteolytic release of intracellular Notch from the
membrane by treatment with inhibitors of gamma secretase
(GSIs). In a number of tumor cell lines carrying HD domain
mutations, blocking proteolytic activation with GSIs triggers cell-
cycle arrest and variable degrees of apoptosis [40,41]. However,
the poor selectivity of GSIs, which inhibit the proteolysis of all four
Notch receptors, and the processing of an expanding list of other
substrates by gamma secretase [16,42,43], constitute significant
potential limitations for this class of anti-tumor agents. Studies in
animal models using the GSI LY 411,575 have shown significant
dose-limiting toxicity in the intestine [44]. The toxic effects of GSIs
in mice appear to result from simultaneous inhibition of Notch1
and Notch2 [29,45], which leads to the accumulation of secretory
cells at the expense of absorptive enterocytes. Clinical trials with
the GSI LY450139 in Alzheimer’s disease patients also identified
diarrhea as the most frequent adverse effect in human phase I
studies [46].
An alternative route that may overcome the toxicity associated
with GSIs is selective targeting of Notch1 with inhibitory
antibodies. In support of this approach, antibodies capable of
selectively modulating Notch3 signaling have been reported
recently [47]. The most potent inhibitory antibodies are directed
against the NRR and are proposed to stabilize the autoinhibited
form of the receptor [47].
In this study, we report the in vitro activities of inhibitory Notch1
monoclonal antibodies derived from cell-based and solid-phase
screening of a phage display library. Two different classes of
antibodies were identified. One class is ligand-competitive, being
directed against the EGF-repeat region of the receptor that
encompasses the ligand-binding domain (LBD), and the second is
allosteric, being directed against the NRR region. Both classes of
antibodies are selective for Notch1, bind Notch1 on the surface of
human tumor cell lines, and inhibit ligand-induced expression of
Notch target genes in cell lines expressing wild-type Notch1
receptors. NRR-targeting antibodies are also capable of recogniz-
ing and inhibiting Notch1 receptors bearing ‘‘class 1’’ NRR
mutations, but are less effective in inhibiting Notch1 activation in
T-ALL cells than GSIs. These findings have implications for
selective targeting of normal and mutated Notch1 receptors with
antibodies as well as our understanding of Notch1 receptor
activation in T-ALL cells.
Materials and Methods
Cell Culture and Reagents
Cancer cell lines (LS-1034, BxPC3, Colo_205, and TALL-1)
purchased from ATCC (Manassas, VA) were maintained at 37uC
under 5% CO2 in RPMI 1640 (Invitrogen, Carlsbad, CA)
supplemented with 10% heat-inactivated (HI) FBS (Hyclone,
Logan, Utah), 2 mM L-glutamine (Invitrogen) and 16Pen-Strep
(Mediatech, Herndon, VA). T-REX
TM-293 and Flp-In
TM -3T3
cell lines purchased from Invitrogen were maintained at 37uC
under 5% CO2 in Dulbecco modified Eagle medium (DMEM)
with high glucose (Invitrogen) supplemented with 10% HI FBS
(Hyclone), 2 mM L-glutamine (Invitrogen), and 16 Pen-Strep
(Mediatech). For the ligand stimulation assays, cells were
resuspended in DMEM high Glucose medium without phenol
red and supplemented only with 10% HI FBS (Hyclone).
Construction of cDNAs and Generation of Stable Cell
Lines
Cell lines stably expressing either full-length wild-type or
chimeric Notch receptors or Notch ligands were generated to test
the binding and potency of Notch antibodies. The human and
Antagonistic Notch1 Antibodies
PLoS ONE | www.plosone.org 2 February 2010 | Volume 5 | Issue 2 | e9094mouse (only Notch1) full-length cDNA sequences coding for
Notch1, 2, and 3, Jag1, and DLL1 were chemically synthesized by
DNA2.0 Technologies (Menlo Park, CA). The cDNA encoding
DLL4 was amplified by RT-PCR from Colo_205 cells following
described protocols [48]. Chimeric human Notch receptors
(Notch1, 2, and 3) were created by inserting the sequence
encoding the DNA binding domain of Gal4 into a Notch cDNA
previously deleted of the sequence encoding most of the RAM
domain and the ankyrin repeat domain as described [35]. Each of
these cDNAs were cloned into the pcDNA5/FRT/TO vector
(Invitrogen) and co-transfected with pOG44 (Invitrogen), a
plasmid encoding Flp recombinase, into T-REX-293 cells (human
wild-type Notch receptors), T-REX-U2OS cells (mouse wild-type
Notch1, chimeric receptors), or 3T3 Flp-In cells (Notch ligands)
using Fugene6 (Roche, Indianapolis, IN) following the manufac-
turer’s protocols. Cell lines with stably integrated cDNAs were
selected with hygromycin (100 mg/ml) (Mediatech). Expression
levels of the Notch proteins were assessed by Western blot and flow
cytometry. The T-REX-U2OS and -293 cells express the Tet
repressor (for tight regulation of gene expression), and also contain
a single genomic FRT (Flp recombinase target) site, which permits
creation of isogenic recombinants containing a single transgene
under the control of tetracycline.
Luciferase Reporter Assays
Assays were performed as described [35]. Stable Flp-In U2OS
cells bearing isogenic transgenes encoding Notch1-, 2-, or 3-GAL4
chimeric receptors were transiently transfected with a pFR-Luc
reporter plasmid (Stratagene, Cedar Crest, TX) containing five
copies of the Gal4 binding site (5X-upstream activation sequence
(UAS)). After 24 hr, cells were treated with doxycycline (2 mg/ml)
(Sigma-Aldrich, St. Louis, MO) in the presence or absence of
Notch antibodies and IgG control, and overlaid at a 1:1 ratio onto
Flp-In-3T3 cells stably expressing Notch ligand or parental Flp-In-
3T3 cells seeded in 96-well plates. Luciferase reporter activities
were measured after an additional 24 hr in whole cell lysates using
the Bright-Glo assay kit (Promega, Madison, WI) and a Victor-
Light luminometer (Perkin-Elmer, Waltham, MA). The potency of
the antibodies was determined with serial dilutions that generate
sigmoid curves. IC50 values were determined using a 3-parameter
logistic curve fit with maximum values arbitrarily fixed at 100%.
In the mouse Notch1 reporter assay, Notch activity in cells stably
expressing the mouse full-length wild-type Notch1 receptor was
determined as described above using a luciferase reporter gene
containing four copies of the CSL binding site (4XCSL-luciferase
reporter gene). To test ligand-independent activation of Notch1
signaling generated by receptors bearing specific T-ALL muta-
tions, T-REX-U2OS cells were transiently transfected with full-
length Notch1 DNA constructs bearing those mutations and the
4XCSL-luciferase reporter gene. Cells were then treated with
antibodies (10 mg/ml) and luciferase activity measured after 24 h
as described above. In these experiments, T-REX-U2OS cells
transiently transfected with the full-length wild-type Notch1
receptor were used as the baseline control.
Ligand Competition Assay
Ligand-competitive binding of antibodies was measured by
Notch1 extracellular domain (ECD) displacement in a dissocia-
tion-enhanced time resolved fluorometric assay (DELFIA). Briefly,
Maxisorp 96-well plates were coated with Notch ligand DLL4
(100 ml/well, R&D Systems, Minneapolis, MN) at 2 mg/ml in D-
PBS (GIBCO-14080) and incubated at 4uC overnight. The coated
plates were blocked with 5% BSA in D-PBS. Notch1 ECD-Fc
fusion protein (Notch1 amino acids Ala19-Gln526) (R&D Systems)
was pre-labeled with europium (Eu) reagent according to the
manufacturer’s procedure (PerkinElmer). Serially diluted Notch1
monoclonal antibodies were preincubated with a fixed amount
(0.5 mg/ml) of Eu-labeled Notch1 ECD-Fc for 2 hr with shaking,
followed by addition to the DLL4 ligand-coated plates. After
incubation at room temperature for 1 hour with slow shaking, the
plates were washed and DELFIAH Enhancement solution (Perkin
Elmer) (100 ml/well) added. Fluorescence signals were read after a
5-min incubation in a Victor3-V plate reader (Perkin Elmer) at
excitation/emission wavelengths of 340/615nm.
Flow Cytometry
Flow cytometric detection of Notch1 was performed with
doxycycline-inducible T-REX-293 cells stably expressing the full-
length Notch1, -2, or -3 receptors, respectively; or the human
cancer cell lines LS-1034, BxPC3, Colo_205, and TALL-1. T-
REX-293 cells were treated with 2 mg/ml doxycycline (Sigma-
Aldrich) for two days to induce Notch expression before collecting
them for staining. Flow cytometric detection of Notch ligands was
performed in Flp-In-3T3 cells stably expressing Jag1, Jag2, and
DLL1 ligands, respectively, using primary antibodies purchased
from R&D Systems. Cells were harvested from tissue culture flasks
using trypsin (Mediatech) and resuspended in PBS with 2% fetal
bovine serum (FBS; Hyclone) (FBS/PBS). Cells (1610
6) were
incubated with 1 mg of each antibody for 40 minutes at 4uC,
followed by washing and resuspension in 0.1 ml of FBS/PBS
containing 1 mg of phycoerythrin-conjugated secondary antibodies
for 30 minutes at 4uC. Cells were then washed, resuspended in
0.34 ml PBS with 1% formaldehyde (Polysciences, Inc., Warring-
ton, PA) and analyzed on a FACSCalibur (Becton Dickinson, San
Jose, CA). The secondary antibodies used were goat anti-human
Fcc specific F(ab’)2 fragments (Jackson ImmunoResearch, West
Grove, PA) to detect the primary anti-Notch1 Abs, donkey anti-
goat IgG (H+L) specific F(ab’)2 fragments (Jackson ImmunoR-
esearch) to detect anti-Jag1 and anti-Jag2, and rat anti-mouse IgG
k light chain antibody to detect anti-DLL1 (BD Pharmingen, San
Diego, CA).
RNA Extraction and QRT-PCR
Parental Flp-In 3T3 cells or Jag2-expressing 3T3 cells were co-
cultured at a ratio 1:1 with LS-1034 or TALL-1 cells in the
presence of 20 mg/ml of each antibody or 5 mM GSI for 19 hr.
Cells were harvested and RNA was isolated using the RNeasy
Mini Kit (Qiagen, Valencia, CA). cDNA was synthesized from
0.5 mg of purified RNA using the High Capacity cDNA Archive
Kit (Applied Biosystems, Foster City, CA) according to the
manufacturer’s instructions. qPCR was performed in triplicate
using 2 ml cDNA sample or control, Brilliant II QPCR Master
Mix with ROX (2X) (Stratagene, Cedar Creek, TX), and the
inventoried probes and primers (Applied Biosystems Assays on
Demand) for human HES1, HES5, DTX1 (Deltex1), and GAPDH.
PCR cycling was performed at 95uC for 10 minutes to allow
enzyme activation, followed by 40 cycles of 95uC for 15 seconds
and 60uC for 1 minute using the Mx3005P QPCR System
(Stratagene). Analysis was performed using MxPro QPCR
Software version 3.0 (Stratagene).
Proliferation Assays
Human T-ALL cell lines (TALL-1, DND-41, KOPT-K1) were
cultured at 37uC under 5% CO2 in RPMI 1640 (Invitrogen)
supplemented with 10% FBS (Hyclone), 2 mM L-glutamine
(Invitrogen), 100 UI/ml penicillin G, and 100 mg/ml streptomycin
(Invitrogen). For growth assays, 30 ml of cell suspension (9610
4
cells/ml) was seeded in 384-well white plates (Corning, Lowell,
Antagonistic Notch1 Antibodies
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culture. Drugs were dissolved in DMSO and antibodies in sterile
PBS. Assessment of the cell growth after 72, 96, and 120 hr of
treatment was carried out by the Cell-Titer Glo luminescence
assay (Promega) in an Envision Multi-label plate reader (Perkin-
Elmer, Waltham, Massachusetts). The assay was done in triplicate
and each experiment was repeated twice. The significance of
differences in cell viability was assessed by the Student t-test.
Synergism was determined by isobologram analysis of dose-
response curves for cells exposed to varying concentrations of GSI
(compound E, Axxora, San Diego, CA), dexamethasone (Sigma),
and/or Notch1 inhibitory antibodies. When used in combination,
the ratio of the two drugs was 1:1, while the ratio of antibody to
drug was 40:1. The degree of synergism was determined by the
combination index (CI) method [49], which was computed from
the dose-response curves with Calcusyn version 2 software (Biosoft,
Cambridge, UK). Significant synergism was defined as a CI,0.7.
Effects of Notch1 Antibodies on Gene Expression in T-
ALL Cells
In order to determine the effects of Notch1 antibodies on the
Notch1-dependent gene expression signature in T-ALL cells, we
first selected a set of genes that defined the Notch1 on versus off
state from Affymetrix microarray expression profiling of 7 Notch1-
mutated T-ALL cell lines treated in duplicate with vehicle versus
the GSI compound E (500 nM) for 24 hr [39]. From a set of ,500
genes with differences of p,0.01 by 2-sided Student’s t-test, 16
sentinel genes were selected to define the Notch1 off signature
based on mean fold changes .1.5 between the Notch1 on versus off
states. Four control genes with stable expression across the two
states were selected to control for well-to-well variability in total
RNA: GAPDH, NFX1, NISCH, and GTF. We next adapted this
signature to an assay that uses ligation-mediated amplification
(LMA) and a Luminex FlexMAP fluorescent bead-based detection
system. Full details of this methodology have been described
elsewhere [50]. Briefly, the 20 genes were subjected to 34 cycles of
amplification by LMA, yielding biotinylated PCR products
containing molecular barcode sequences. These PCR products
were hybridized in solution to beads dyed with unique fluorescent
colors containing complementary barcode sequence. Following
hybridization and staining with streptavidin-phycoerythrin (SA-
PE), the beads were analyzed by dual-color flow cytometry, in
which the bead color identifies the gene of interest and PE
intensity the quantity of transcript. DND-41 cells were treated
with control antibody (10 mg/ml) (6 replicates), NRR WC75
Notch1 antibody (10 mg/ml) (7 replicates), DMSO (0.08%) (6
replicates), or GSI (1 mM) (14 replicates) for 72 hr and then
analyzed for gene expression. To normalize measurements within
each experiment, expression of Notch marker genes was expressed
relative to the average expression of the four control genes. We
also evaluated the overall performance of the signature by
calculating two summary scores combining information about all
of the signature genes: the summed score and the weighted
summed score. The summed score metric combined expression
ratios by summing them with a sign determined by the expected
direction of regulation as determined from the positive controls
(GSI-treated). The weighted summed score metric is a variant of
the summed score metric that combines expression ratios by
summing them with a weight and sign determined by the signal-to-
noise ratio of the positive control (GSI-treated) and negative
controls (DMSO-treated). Signal-to-noise ratio is defined by:
Wi~mi1{mi2=si1zsi2
where mi1 represents the mean expression of samples from class 1
for feature i and si1 represents the standard deviation of class 1 for
feature i.
Antibody-Mediated Immunoprecipitation of the Notch1
Ectodomain
Notch ectodomains were cloned into the pLEXm mammalian
expression vector with C-terminal His6 tags, expressed in HEK-
293T cells using a PEI-based transfection protocol and harvested
after 3 days. Whole cell extracts were prepared by lysis with RIPA
buffer containing 1:250 protease inhibitors followed by centrifu-
gation to remove cellular debris. Lysates were mixed with 5–10 mg
primary antibody overnight at 4uC, then with 50 mL Protein A-
agarose suspension for an additional 2 hours. Beads were then
collected by centrifugation, washed 3 times with PBS, and
resuspended in 50 mL2 6SDS sample buffer containing 100mM
DTT. Samples were boiled for 5 minutes and run on a 5–20%
Tris-Glycine gel, then transferred to a nitrocellulose membrane at
15V for 1 hour. Blots were washed twice with Tris-buffered saline,
pH 7.5 (TBS) and blocked in TBS +3% BSA for 1 hour.
Incubation with Penta-His antibody (1:1000) was performed
overnight in TBS +3% BSA, followed by incubation with goat
a–mouse antibody (1:10,000) in TBS +10% milk for 1 hour.
Three wash steps were done following the incubation with primary
antibody (two with TBS-Tween-0.2% Triton-X (TBST) and one
with TBS), and four washes with TBST were done following the
incubation with secondary antibody. Blots were exposed for 10–
20 minutes and analyzed using an Alpha Innotech gel documen-
tation system.
Calcium-Dependence of Epitope Binding by Anti-NRR
Antibodies
A plasmid encoding the human Notch1 NRR (residues E1446-
Q1733; Genbank ID 148833507) was modified to contain a N-
terminal hexahistidine tag followed by a TEV cleavage site. The
Notch1 NRR precursor was prepared essentially as described for
the loopout form of the Notch1 NRR [37]. The purified protein
was labeled with EZ-Link NHS-PEG4-Biotin (Pierce-Thermo,
Rockford, IL) according to the manufacturer’s instructions.
Biotinylated Notch1 NRR was then captured onto neutravidin-
coated 96-well plates. Binding of the anti-NRR antibodies was
allowed to proceed for one hour in Tris buffer (25 mM, pH 7.4),
containing NaCl (150 mM), CaCl2 (5 mM), 0.05% Tween, and
0.5% BSA. Antibody binding was detected with a goat anti-human
antibody conjugated to horseradish peroxidase using the fluoro-
genic substrate quantaBlu (Pierce-Thermo).
Results
Notch1 Antibodies Bind to Distinct Domains (LBD or
NRR) of the Notch1 Receptor
A total of 16 high-affinity antibodies against Notch1 were
selected from a phage library, using both cell-based and
recombinant protein panning approaches. The details of the
panning strategy and the identification, cloning and ranking of hits
by affinity will be described elsewhere. All antibodies were shown
by flow cytometry to bind to full-length Notch1 overexpressed in
HEK cells (Table 1 and data not shown). Since antibodies against
the Notch1 extracellular domain were likely to interfere with
receptor-ligand interactions, we first evaluated all antibodies in a
ligand competition assay with recombinant DLL4 and the Notch1
ectodomain (EGF repeats 1–13), which includes the ligand binding
domain (LBD; EGF repeats 11–13). As shown for a subset of
Antagonistic Notch1 Antibodies
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binding of the Notch1 ectodomain to immobilized DLL4. Fixed
dilutions of antibodies were used for this initial characterization, as
the intent was to classify the antibodies by mechanism rather than
to establish their relative potencies. Antibodies that failed to
compete with DLL4 binding, such as WC75 and WC629
(Figure 1), did not recognize EGF repeats 1–13. Instead, these
antibodies were found to bind to the negative regulatory region
(NRR) of Notch1 (supplemental Figure S1). In contrast, none of
the ligand-competitive antibodies bound to recombinant NRR
(data not shown). A total of seven antibodies (listed in Table 1)
were selected for further characterization, five ligand-competitive
antibodies (referred to as LBD antibodies) and two antibodies
recognizing the NRR (referred to as NRR antibodies).
LBD and NRR Antibodies Are Specific Notch1 Antagonists
To evaluate the functional activity of the LBD and NRR
antibodies, we generated a panel of stable T-REX-U2OS cell lines
expressing Notch1-, Notch2-, or Notch3-Gal4 fusion receptors.
Notch signaling in these reporter cell lines was monitored by
transient transfection of a Gal4-luciferase reporter plasmid. To
activate Notch signaling, reporter cell lines were co-cultured with
3T3 cell lines stably overexpressing various Notch ligands.
The five LBD and two NRR antibodies were characterized for
their effect on Jag2-induced Notch signaling, using a well-
characterized NIH 3T3 cell line expressing Jag-2 [51–52]. The
ligand-competitive LBD antibodies were able to block Jag2-
stimulated Notch1 activity completely (Figure 2A and Table 1).
The basal reporter activity in the presence of parental Flp-In-3T3
cells (no ligand expression) was neither significantly inhibited nor
stimulated by these antibodies (data not shown), indicating that,
despite their potential to crosslink Notch1, free LBD antibodies do
not have agonistic activity. The NRR-specific antibodies were also
potent antagonists of Jag2-dependent Notch1 signaling (Figure 2B
and Table 1), presumably through allosteric stabilization of the
NRR domain in a metalloprotease-resistant autoinhibited confor-
mation. The generally greater potency of the NRR antibodies as
compared to the LBD antibodies correlated with a higher affinity
for Notch1-expressing cells, as assessed by flow cytometry
(Table 1). However, at saturating concentrations, the NRR
antibodies maximally inhibited Notch1 signaling by 70 to 80%,
whereas LBD antibodies were able to completely inhibit the
Notch1 activation by Jag2. As seen with the LBD antibodies, the
NRR-binders did not exhibit detectable agonist activity in co-
culture assays using parental 3T3 Flp-in cells.
The specificity of both classes of antibodies for Notch1 as
opposed to Notch2 or Notch3 was evaluated in reporter assays
with Notch-Gal4 fusion receptors. Neither LBD nor NRR
antibodies significantly inhibited ligand-stimulated Notch2-Gal4
and Notch3-Gal4 signaling (Figure 2C). Species cross-reactivity
was tested in T-REX-U2OS cells stably expressing murine Notch1
and transiently transfected with a CSL-luciferase reporter. In co-
culture experiments with 3T3 cells expressing human Jag2, greater
than 50% inhibition of mouse Notch1 was seen with several of the
antibodies at 167 nM (Figure 2D), suggesting that future efficacy
and tolerability studies of these antibodies can be conducted in
mouse models.
Because we have been unable to create Notch4 reporter lines
that generate a luciferase signal in response to ligand stimulation,
we tested the antibodies for specificity toward Notch1 as opposed
to Notch4 by comparing the ability of representative LBD and
NRR antibodies to immunoprecipitate the Notch1 and Notch4
extracellular domains. Western blot analysis (supplemental Figure
S2) showed that the allosteric antibody WC75 and the ligand
competitive antibody WC613 both immunoprecipitated Notch1
but not Notch4.
Ligand Dependence of Inhibitory LBD and NRR
Antibodies
Based on current models of Notch receptor activation, the
inhibitory activities of LBD antibodies were expected to show a
stronger dependence on the activating Notch1 ligand than NRR
antibodies, which are not ligand-competitive (Figure 1). We
therefore compared the ability of these two classes of antibodies to
Figure 1. Ligand-competition by Notch1 antibodies. A panel of
Notch1 antibodies was tested in a ligand competition assay (DELFIA) for
binding to EGF repeats 1–13 of Notch1. This assay measures inhibition
of binding of Eu-labeled Notch1 ECD-Fc fusion protein to immobilized
DLL4. The ECD-Fc fusion comprises EGF repeats 1–13 (Ala19-Gln526)
which includes the ligand binding domain (EGF repeats 11–13) but
lacks the NRR. Human IgG and competing soluble DLL4 were used as
negative and positive controls, respectively. The data were normalized
with respect to the ‘‘no blocker’’ controls and curve fitted using a fixed
100% plateau, shared slopes and variable base lines. Error bars
represent the standard deviation from triplicate values.
doi:10.1371/journal.pone.0009094.g001
Table 1. Inhibition of Jag2-mediated Notch1 signaling by
Notch1 antibodies.
Antibody
Target
domaina
Notch1
Bindingb Notch1 inhibition
EC50 (nM)
c % maximal
WC613 LBD ++ 5( 63) 96 (61)
WC133 ++ 10 (65) 95 (63)
WC155 ++ 57 (637) .80
WC179 + 43 (616) .70
WC97 + 170 (625) .70
WC75 NRR ++++ 0.13 (60.09) 75 (69)
WC629 +++ 6( 62) 70 (63)
aLBD: EGF-like repeats (1–13) encompassing the ligand-binding domain; NRR:
Negative regulatory region.
bFACS score on Notch1 expressing HEK cells: MFI,100 (+); MFI 100–500 (++);
MFI 501–1000 (+++); MFI.1000 (++++); MFI=Mean Fluorescence Intensity.
cCo-culture assay with Notch1-Gal4 T-REX-U2OS cells transfected with UAS-
luciferase reporter and Flp-In-3T3-Jag2 cells; normalized to signal obtained
with Flp-In-3T3 parental cell line; average and standard deviation from at least
4 independent experiments.
doi:10.1371/journal.pone.0009094.t001
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expressing Jag1, Jag2, DLL1 or DLL4. Expression of Jag1, Jag2,
and DLL1 was confirmed by flow cytometry using specific
antibodies in each of the stable 3T3 cell lines (data not shown).
It was not possible to determine the levels of DLL4 by flow
cytometry due to lack of an appropriate antibody, but luciferase
reporter assays using 3T3-DLL4 cells confirmed the ability of
DLL4 to strongly activate Notch signaling. As expected, the
antagonistic activity of LBD antibody WC613 was strongly
dependent on the particular ligand-expressing cell line used to
activate Notch1 (Figure 3A). 3T3-Jag1 mediated signaling was
most sensitive to inhibition, while 3T3-DLL4 signaling was most
resistant. The same rank order was observed with the other LBD
antibodies (Table 2). While it is tempting to speculate, the
variation in EC50 values cannot be solely attributed to the identity
of the particular ligand since we were not able to quantify the
ligand levels on the various 3T3 cell lines in absolute terms. In
contrast to the LBD antibodies, the activities of both NRR
antibodies were minimally dependent on the nature of the ligand-
expressing cell line and both antibodies inhibited DLL4 signaling,
albeit to a maximum of 50% to 60% (Figure 3B, Table 2). These
data are consistent with the current models of ligand-dependent
Notch receptor activation, i.e., that LBD antibodies compete with
ligands for access to the Notch1 LBD, whereas NRR antibodies
allosterically inhibit ligand-induced conformation changes in the
NRR.
Notch1 Antibodies Modulate Notch Target Gene
Expression in Cancer Cell Lines
Notch1 signaling is increased in a variety of cancers and
activates downstream target genes, including HES1, HES5, DTX1,
NRARP, and c-MYC [7,18,38,53]. Two human lines expressing
wild-type Notch1 receptors, the colorectal carcinoma cell line LS-
1034 and the T-ALL cell line TALL-1, were used to test the ability
Figure 2. Inhibition of Jag2-dependent Notch signaling by Notch1 antibodies. Notch1 reporter activity was measured in co-culture assays
with T-REX-U2OS Notch1-Gal4 reporter cells and Flp-In-3T3 cells expressing human Jag2. Representative examples are shown for each of the LBD and
NRR antibodies. Error bars represent the standard deviation from triplicate values. (A) Inhibition of Notch1-Gal4 signaling by LBD antibodies WC613
(open circles), WC133 (closed circles), WC179 (open triangles), and WC97 (closed triangles). (B) Inhibition of Notch1-Gal4 signaling by NRR antibodies
WC75 (closed circles) and WC629 (open circles). (C) The Notch isoform specificity of Notch1 antibodies was tested in co-culture assays with T-REX-
U2OS Notch-Gal4 reporter cells (human Notch1, 2, and 3) and Flp-In-3T3 cells expressing human Jag2. NRR and LBD antibodies were used at a fixed
antibody concentration of 167 nM. Reporter cell lines used: hNotch1-Gal4 (black bars), hNotch2-Gal4 (lined bars), hNotch3-Gal4 (cross-hatched bars).
The activity of a UAS-luciferase reporter transiently expressed in the T-REX-U2OS Notch-Gal4 cells was normalized to untreated controls. IgG isotype
controls are shown. Error bars represent standard deviation. (D) The species specificity of Notch1 antibodies was tested in co-culture assays with T-
REX-U2OS cells expressing wild-type mouse Notch1 and Flp-In-3T3 cells expressing human Jag2. NRR and LBD antibodies were used at a fixed
concentration of 167 nM. The activity of a 4xCSL-luciferase reporter transiently expressed in the T-REX-U2OS cells was normalized against the non-
specific IgG control. Error bars represent standard deviation.
doi:10.1371/journal.pone.0009094.g002
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Notch signaling was induced by co-culture of these cell lines with
3T3 cells expressing Jag2. Although other Notch receptors are
expressed in these cells (i.e., Notch2 and 3 was detected in LS-
1034 cell lysates by Western blot, and Notch3 on the surface of
TALL-1 cells by flow cytometry; data not shown), the specificity of
the antibodies (unlike GSI) allows one to assess the effects of
Notch1 inhibition per se. In LS-1034 cells, ligand-dependent
transactivation of Hes1 transcription was inhibited significantly by
each of the antibodies tested at saturating antibody concentrations.
The LBD antibodies (e.g., WC613, WC133) almost completely
inhibited Hes1 transactivation, while the NRR antibodies (WC75,
WC629) were partially inhibitory (Figure 4). A similar correlation
was observed in TALL-1 cells, in which the ligand-dependent
transactivation of both HES5 and DTX1 was also inhibited by all
of the antibodies tested at saturating antibody concentrations, with
the LBD antibodies being more effective than the NRR antibodies
(Figure 4). These results correlate with the ability of the LBD and
NRR antibodies to totally or partially, respectively, inhibit ligand-
dependent Notch1 activation in the reporter assays. Because other
Notch family members besides Notch1 may contribute to basal
and induced Notch signaling in these cells, we compared the
effects of the antibodies with a ‘‘pan-Notch inhibitor’’, the gamma-
secretase inhibitor (GSI). At a concentration of 5 mM, GSI
inhibited ligand-dependent activation, and suppressed expression
below the basal level observed in co-culture with the parental 3T3
Flp-in cells, as might be expected based on the ability of GSIs to
block the activity of all Notch family members expressed on the
tumor cells (Figure 4).
As described above, the potency of the antibodies in the reporter
assays correlated with their affinity for Notch1, as assessed by flow
cytometry conducted on cells engineered to express Notch1 stably
(Table 1). To establish a correlation between phenotypic response
and the binding affinity of the LBD and NRR antibodies to Notch1
expressed on the surface of cancer cells, flow cytometry was
performed with LS-1034, BxPC3, Colo_205, and TALL-1 cells
using saturating concentrations of the WC75 (NRR) and WC613
(LBD) antibodies. All the cell lines showed detectable levels of
Notch1 on the cell surface (Figure 5) that correlated with levels of
Notch1 detected in Western blots of whole cell lysates with an
antibody directed against intracellular Notch1 (not shown). The
relative binding affinities of NRR and LBD antibodies for Notch1
varied among cancer cell lines. With LS-1034 cells, NRR antibodies
showedgreaterbindingthanLBDantibodies,whiletheconversewas
true for TALL-1 cells (Figure 5). The explanation for this cell line-
dependent variation in the stoichiometry of binding of NRR and
LBDantibodiesisnotreadilyapparent,andlikelytobecomplex.Itis
possible, for example, that expression of various competing ligands,
epitope masking by cell-type specific glycosylation, or other post-
translational modifications of Notch1 [54] may differentially affect
the binding of antibodies to their respective epitopes.
Notch1-dependent proliferation has been previously reported in
some cancer cell lines [55–57]. To evaluate the anti-proliferative
effect of Notch1 antibodies on a cell-line derived from a solid
tumor, LS-1034 cells were grown in monolayer culture in the
presence or absence of the Notch1 antibodies for up to 96 hr.
Although these cell lines express wild-type Notch1 on their cell
surface (Figure 5), treatment with anti-Notch1 antibodies at
saturating concentrations (0.1 mM) did not affect their proliferative
capacity (data not shown).
Figure 3. Ligand-dependence of Notch1 inhibition by LBD and NRR antibodies. Notch1 signaling in T-REX-U2OS Notch1-Gal4 cells was
stimulated by co-culture with Flp-In-3T3 cells expressing Jag2 (closed circles), Jag1 (open circles), DLL1 (closed triangles), or DLL4 (open triangles).
The activity of a UAS-luciferase reporter transiently expressed in the T-REX-U2OS Notch-Gal4 cells was normalized to untreated controls.
Representative examples of Notch1-Gal4 reporter inhibition are shown for LBD antibody WC613 (A) and for NRR antibody WC629 (B).
doi:10.1371/journal.pone.0009094.g003
Table 2. Inhibition of signaling of various Notch1-ligand pairs
by Notch1 antibodies.
Antibody Domaina EC50 (nM)
b
Jag2 Jag1 DLL1 DLL4
WC613 LBD 5 (63) 0.3 (60.2) 5 (62) .330
WC133 10 (65) 0.7 (60.1) 7 (63) .330
WC155 57 (637) 1.3 (61) 48 (66) .330
WC179 43 (616) 3.4 (63) 28 (616) .330
WC97 170 (625) 4 (62) 18 (610) .330
WC75 NRR 0.13 (60.09) 0.1 (60.1) 0.3 (60.3) 0.32 (60.3)
WC629 6 (62) 2 (62) 6 (64) ,50
c
aLBD: EGF-like repeats (1–13) encompassing the ligand-binding domain; NRR:
Negative regulatory region.
bCo-culture assay with Notch1-Gal4 T-REX-U2OS cells transfected with UAS-
luciferase reporter and Flp-In-3T3 cells overexpressing the ligands Jag2, Jag1,
DLL1, and DLL4, respectively; normalized to signal obtained with Flp-In-3T3
parental cell line; average and standard deviation from at least 4 independent
experiments.
cInflection points poorly defined.
doi:10.1371/journal.pone.0009094.t002
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PLoS ONE | www.plosone.org 7 February 2010 | Volume 5 | Issue 2 | e9094Figure 4. Notch1 antibodies inhibit Notch target gene expression in cancer cell lines. The ability of antibodies (20 mg/ml) or GSI (5 mM) to
inhibit Notch1 target gene expression (HES1, HES5, DTX1) was analyzed by quantitative real time PCR (qRT-PCR) of mRNA extracted from LS-1034 or
TALL-1cancercelllinesco-culturedwithFlp-In3T3-Jag2cellsfor22 hat37uC.qRT-PCRwasperformedintriplicatewiththeStratageneMx3005P(Agilent
Technologies, BioCrest Manufacturing, Cedar Creek, TX). Values were normalized on the basis of GAPDH mRNA expression. Gene expression (% mRNA
remaining) normalized to Jag2-dependent signal (100%) from at least four experiments is represented (error bars indicate error standard, *p,0.05).
doi:10.1371/journal.pone.0009094.g004
Figure 5. LBD and NRR antibodies bind to cancer cell lines. Notch1 surface expression in LS-1034, TALL-1, BxPC3, and Colo_205 cancer cell
lines was examined by flow cytometry (FACSCalibur, BD BioSciences, San Jose, CA) after staining of cells with the LBD antibody WC613 (green line) or
NRR antibody WC75 (red line), and R-PE-conjugated anti-human IgG antibody (Jackson ImmunoResearch,, Inc., West Grove, PA). An irrelevant human
IgG isotype antibody (hIgG) (blue line) was used as negative control.
doi:10.1371/journal.pone.0009094.g005
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ALL Cells by NRR Antibody WC75
Leukemogenic point mutations in the NRR of Notch1 cause
conformational changes that lead to ligand-independent S2
cleavage [35], suggesting that LBD antibodies should have little
effect on the activation of receptors bearing such mutations. In
contrast, NRR antibodies raised against wild-type receptor might
be able to inhibit such mutated receptors if conformational
changes induced by the mutations are not so great as to preclude
antibody binding and if antibody binding prevents the adoption of
conformations that are permissive for metalloprotease cleavage.
To initially test this idea, Notch1 receptors bearing diverse NRR
mutations were transiently expressed in U2OS cells, and
antibodies were scored for their effect on activation of a Notch-
dependent luciferase reporter gene. Mutations tested included six
class I mutations, which destabilize the NRR; one class II
mutation (from the T-ALL cell line P12-Ichikawa) consisting of a
direct repeat in exon 27 of Notch1 that duplicates a 14 amino acid
sequence containing the S2 cleavage site [26]; one juxtamembrane
class III mutation (from the T-ALL cell line Jurkat) consisting of a
direct repeat in exon 28 of Notch1 that inserts a 17 amino acid
sequence [58]; and VSV, an artificial mutation that inserts 14
amino acids into the juxtamembrane region [58].
All class I mutations tested (L1594P, L1597H, R1599P,
L1601P, L1679P, V1677D) were inhibited by the NRR antibody
WC75 at 10 mg/ml (Figure 6A), whereas LBD antibodies generally
had little effect on these mutated forms of Notch1 (data not
shown). In contrast, juxtamembrane insertional mutations (Jurkat,
P12-Ichikawa, and VSV) were completely refractory to inhibition
by both NRR and LBD antibodies (Figure 6B and data not
shown). These data indicate that NRR antibodies are capable of
recognizing and stabilizing Notch1 receptors bearing common
class I mutations, and provide additional support for the idea that
juxtamembranous insertional mutations activate Notch1 through a
mechanism distinct from that of class I mutations [35].
We next asked whether the WC75 antibody could inhibit the
expression of Notch1 target genes in the T-ALL cell line DND-41
which expresses Notch1 receptors bearing the compound class I
mutation L1594P/D1610V. To look at the effects of WC75 on the
Notch signature, we used a luminex bead-based assay that depends
on ligation-mediated amplification of mRNAs captured by
oligonucleotides on beads [50]. The pattern of gene expression
changes induced by WC75 resembled that produced by the GSI
compound E (Figure 7A), indicating that WC75 is capable of
inhibiting this particular form of mutated Notch1, but the extent of
inhibition by WC75 across the entire Notch1 signature was less
than that produced by GSI. The relatively weak inhibitory effect of
WC75 on Notch1 target gene expression was confirmed by qRT-
PCR analysis of two well-characterized Notch-dependent tran-
scripts, DTX1 and c-MYC (Figure 7B).
Growth assays were also conducted to compare the effects of
WC75 and GSI on T-ALL cell growth (Figure 8). WC75 reduced
the growth of DND-41 cells and KOPT-K1 cells (which bear a
L1601P class I NRR mutation), but to a significantly lesser degree
than GSI. Isobologram studies showed that WC75 (10 mg/ml) has
weakly synergistic antiproliferative effects on KOPT-K1 cells
when used in combination with dexamethasone (combination
index=0.45, not shown), whereas GSI produced stronger
synergistic effects (combination index=0.1, not shown). Taken
together, these studies show that in T-ALL cells, signals generated
by Notch1 receptors bearing class I NRR mutations are not
inhibited as effectively by NRR antibodies as they are by GSI.
Discussion
Notch pathway inhibitors represent an opportunity for targeted
treatment of several different human cancers. Tumors for which
inhibition of Notch signaling may be particularly desirable include
breast cancer, where high levels of Notch1 signaling are associated
with poorer prognosis [28,31], and T-ALL, in which activating
mutations in Notch1 are found frequently and where treatment
Figure 6. NRR antibody WC75 inhibits ligand-independent signaling by Notch1 receptors harboring T-ALL-associated mutations. T-
REX-U2OS cells were transiently co-transfected with a 4xCSL-luciferase reporter construct and full-length Notch1 cDNA constructs encoding mutated
receptors that exhibit ligand-independent activation of Notch signaling: (A) class I point mutations; (B) insertional mutations p12 (class II), Jurkat (class
III) and VSV (juxtamembrane). Activity of luciferase after treatment with the NRR WC75 Notch1 antibody (10 mg/ml) was measured in cell lysates using
the Bright-Glo assay kit (Promega). Reporter activity induced by the wt-Notch1 construct was used as baseline control. Error bars represent standard
deviation.
doi:10.1371/journal.pone.0009094.g006
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[34,40,41].
In the studies reported here, we characterize the in vitro activity
of Notch1 monoclonal antibodies derived from cell-based and
solid-phase screening of a phage display library. Antibodies could
be grouped into two mechanistically distinct classes, ligand-
competitive antibodies targeting the EGF repeat 1–13 region
and allosteric, NRR-binding antibodies. Antibodies in both groups
have potencies in the nanomolar to picomolar range and are
highly specific for Notch1. The antibodies recognize endogenous
receptors on tumor cell lines, inhibit the expression of Notch target
genes in some tumor cell lines, and block Notch-dependent
transcription in transfected cells. Ligand-competitive antibodies
bind to the EGF-repeat 1–13 region (LBD) of the receptor and
show a strong dependence on the particular ligand-expressing cell
line used for co-culture. The variation in antagonist potency as a
function of activating ligand might arise for a number of different
reasons. Possibilities include not only differences in the intrinsic
affinity of Notch1 for various ligands, but also variation in ligand
expression level, differential modulation of ligand affinity by
glycosyltransferase modification of Notch1, variable ligand-
mediated cis-inhibition in Notch-expressing cells, etc. Additional
mechanistic studies will be required to evaluate the potential
therapeutic use of these ligand-competitive antibodies. For
Figure 7. Comparison of the effects of NRR antibody WC75 or GSI on Notch1-dependent target gene expression in DND-41 cells. A)
Following treatment of DND-41 cells for 72 hr with either DMSO (0.08%), GSI (compound E, 1 mM), control nonspecific human antibody (10 mg/ml), or
NRR antibody WC75 (10 mg/ml), the expression levels of 20 genes that define a T-ALL-specific Notch1 signature were measured with a ligation-
mediated amplification/fluorescent bead-based detection system. Each column represents an independent experimental replicate. Dark red indicates
high gene expression and dark blue low gene expression. Notch marker gene expression is depicted as a ratio of the expression of the marker gene
relative to the mean of four control genes. The summed score combines expression ratios by summing them with a sign determined by the expected
direction of regulation as determined from the positive controls (GSI-treated). The weighted summed score metric is a variant of the summed score
metric that combines expression ratios by summing them with a weight and sign determined by the signal-to-noise ratio of the positive control (GSI-
treated) and negative controls (DMSO-treated). B) DTX1 and c-MYC expression levels assessed by qRT-PCR following 3 days of treatment of DND-41
cells with control nonspecific human antibody (IgG, 10 mg/ml), WC75 NRR-N1 antibody (10 mg/ml), or GSI (compound E, 1 mM). Expression of each
transcript was determined in triplicate, and each experiment was repeated three times.
doi:10.1371/journal.pone.0009094.g007
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[33], may be relatively insensitive to the LBD antibodies reported
here. On the other hand, cancers in which over-expression of Jag1,
Jag2, and DLL1 are associated with poor survival, such as prostate
[60] and breast [61–63] carcinomas, CNS tumors [57], and
multiple myeloma [62], may be tractable targets.
The second group of inhibitory antibodies binds to the NRR,
the activation switch of the receptor located ,1000 residues C-
terminal to the ligand-binding EGF repeats. The mechanism of
inhibition of NRR antibodies with respect to ligands appears to
be allosteric, with little dependence on the type of ligand used for
transactivation. However, the NRR antibodies were incapable of
completely inhibiting ligand-dependent Notch1 activation;
whether this stems from masking of the binding epitope in a
subset of receptors, residual intrinsic responsiveness of antibody-
bound receptors, or some other mechanism remains to be
determined. Of note, binding of the WC75 and WC629 NRR
antibodies is abrogated by EDTA (Supplemental Figure S1),
which relaxes the structure of the NRR [3,59]. Together these
data indicate that NRR antibodies bind to a conformational
epitope on the auto-inhibited conformation of the NRR and
prevent adoption of the open, protease-accessible conformation
upon ligand interaction.
Cell culture studies with human solid tumor cell lines,
including LS-1034, showed that the LBD and NRR antibodies
have no significant anti-proliferative effect. The lack of anti-
proliferative activity in monolayer culture is not unexpected, as
even GSIs lack activity against many solid tumor cells in culture,
despite their activity in in vivo models (unpublished data). Growth
inhibition and apoptosis have been reported following siRNA
mediated knock-down of Notch1 [55,57,65]. It is possible that
down-regulation of Notch protein levels may have a greater
impact than inhibition of ICN1 production on cross-talk with
other pathways that drive cancer growth [66,67], as well as the
expression of key factors involved in cell cycle progression [68].
Cell culture models of physiologically relevant Notch-ligand
interactions have been reported [55,57]; however, in vivo models
will be required to conclusively evaluate the therapeutic potential
of Notch1 antibodies.
Of interest, the NRR antibodies bind and inhibit ligand-
independent activation of Notch1 receptors harboring T-ALL
associated mutations, while LBD antibodies generally do not.
Nevertheless, it appears that in contrast to GSIs, the ability of
NRR antibodies to inhibit growth is likely to be limited to T-ALL
lines bearing class I Notch1 mutations, as receptors harboring
unusual juxtamembrane insertional mutations [35,58] were
completely resistant to the inhibition by NRR antibodies. In
addition, even Notch1 receptors harboring class I mutations
appear to be partially resistant to inhibition, particularly in T-ALL
cells. In part, this may be due to the allosteric mechanism of
inhibition by NRR antibodies which, as shown for wild-type
Notch1 signaling, results in incomplete inhibition. An additional
possibility is that aberrant trafficking of such receptors in T-ALL
results in intracellular proteolysis and activation in vesicular
compartments that are not accessible to antibody, but can be
reached by membrane-permeable GSIs.
Similar to the results with human solid tumor cell lines
expressing wild-type Notch1, the proliferation of T-ALL cell lines
was minimally affected by NRR antibodies. However, T-ALL cell
lines are significantly more sensitive to GSI-mediated inhibition of
Notch1 activation. Together these data suggest that the therapeu-
tic potential of NRR antibodies is higher in tumors that have intact
extracellular Notch1 and depend on ligand for Notch1 activation;
breast cancer is one such tumor. It is also possible that such anti-
Notch antibodies may have value as inhibitors of stromal activities
that support tumor cell growth, such as angiogenesis, which
depends on a DLL4-Notch1 signaling axis [32,69]. In addition to
their therapeutic potential, these antibodies may find utility as
biomarker tools, for detection of Notch1 on the surface of tumor
cells, and as probes of Notch1 function and signaling mechanisms.
Supporting Information
Figure S1 Calcium-dependence of epitope binding by anti-NRR
antibodies. Biotinylated Notch1 NRR was captured onto neu-
travidin-coated 96-well plates. Binding of the NRR antibodies was
allowed to proceed for one hour in Tris buffer (25 mM, pH 7.4),
containing NaCl (150 mM), CaCl2 (5 mM), 0.05% Tween, and
Figure 8. NRR WC75 Notch1 antibody proliferation of T-ALL cells. Proliferation of DND-41 (L1594P/D1610V NRR-N1 mutations) and KOPT-K1
(L1601P NRR-N1 mutation) cells (2.5610
3 cells/well) was assessed in a 384-well format for up to 5 days in the presence of either the WC75 antibody
(10 mg/ml) or the gamma secretase inhibitor compound E (GSI, 100 nM). Growth inhibition was measured by CellTiter-GloH (Promega).
doi:10.1371/journal.pone.0009094.g008
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absence of EDTA, and the (+) column indicates the presence of
EDTA (10 mM). Antibody binding was detected with a goat anti-
human antibody conjugated to horseradish peroxidase using the
fluorogenic substrate quantaBlu (Pierce-Thermo). The three
control experiments were performed by omitting the Notch1
NRR antigen (no Notch1 NRR), the anti-Notch1 NRR (no 1-Ab),
or the secondary anti-human antibody (no 2-Ab).
Found at: doi:10.1371/journal.pone.0009094.s001 (2.04 MB TIF)
Figure S2 Antibodies WC75 (A) and WC613 (B) immunopre-
cipitate Notch1 but not Notch4. 293T cells were transfected with
plasmids expressing the complete ectodomains of Notch1 or
Notch4 containing His6-tags at their C-terminal ends. Immuno-
precipitation was performed after lysis of the transfected cells.
WCE: whole cell extracts; FT: supernatant remaining after
immunoprecipitation; IP: WC75 (A) or WC613 (B) immunopre-
cipitate. Detection was performed with an anti-His6 antibody.
His6-tagged molecular weight markers are loaded in the leftmost
lane.
Found at: doi:10.1371/journal.pone.0009094.s002 (0.44 MB TIF)
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